← Back to Clinical Trials
Recruiting NCT06508268

Language, Speech and Motor Function in MCI Due to AD and Alzheimer's Disease

Trial Parameters

Condition Alzheimer's Disease
Sponsor Hanze University of Applied Sciences Groningen
Study Type OBSERVATIONAL
Phase N/A
Enrollment 208
Sex ALL
Min Age N/A
Max Age N/A
Start Date 2024-07-12
Completion 2025-02-09
Interventions
GAITRite walkway system OR 4-meter walking speed testJamar hand dynamometerPicture description task

Brief Summary

The goal of this observational cross-sectional study is to explore the characteristics of language, speech, and motor function in persons with Mild Cognitive Impairment due to Alzheimer's disease ("MCI due to AD") and persons with mild and moderate Alzheimer's disease ("AD"). This study aims to: * Explore motor, speech, and language functions in MCI due to AD and mild and moderate AD. * Combine the characteristics of motor, language, and speech functions to gain more insight into the association of language, speech, and motor changes during MCI due to AD and mild and moderate AD. Researchers will compare the outcomes to an age-matched control group without cognitive impairment. Participants will undergo: * Two motor function tests to assess gait and hand grip strength. * Four language and speech function tests to assess spontaneous speech and verbal fluency..

Eligibility Criteria

Inclusion Criteria: A subject with MCI with a likelihood of underlying AD pathophysiology must meet the following criteria: * Established diagnosis of MCI due to AD with a likelihood according to NIA-AA criteria (Albert et al., 2011). * A score of stage three on the Global Deterioration Scale (GDS) (Reisberg et al., 1982). A subject with AD must meet the following criteria: * Established diagnosis of AD (amnestic or non-amnestic) or etiologically mixed presentation of AD according to DSM-5 (American Psychiatric Association, 2013) or NINCDS-ARDRA criteria (Jack et al., 2018; McKann et al., 2011). * The following scores on the Global Deterioration Scale (GDS): four for mild AD, five for moderate AD (Reisberg et al., 1982). All subjects of the control group must meet the following criteria: * A score of stage one or two on the Global Deterioration Scale (GDS) (Reisberg et al., 1982). * They are age-matched with the MCI due to AD or AD patients included in the study. All subjects must meet

Related Trials